WHAT IS CLAIMED:

1. A pharmaceutical formulation comprising:

(a) a first antibody or antigen-binding fragment thereof that binds to a spike protein of SARS-CoV-2 and optionally a second antibody or antigen-binding fragment thereof that binds to a spike protein of SARS-CoV-2,

(b) histidine and/or a pharmaceutically acceptable salt thereof,

(c) arginine and/or a pharmaceutically acceptable salt thereof or sucrose, and

(d) polysorbate,

wherein the formulation has a pH of about 5.5 to 6.5.

2. The pharmaceutical formulation of claim 1, wherein the formulation comprises about 15 mM to about 25 mM of (b), optionally wherein the formulation comprises about 20 mM of (b).

3. The pharmaceutical formulation of claim 1 or 2, wherein (b) is histidine/histidine-HCl.

4 The pharmaceutical formulation of any one of claims 1-3, wherein the formulation comprises about 200 to about 250 mM of (c).

5. The pharmaceutical formulation of any one of claims 1-4, wherein (c) is arginine and/or a pharmaceutically acceptable salt thereof.

6. The pharmaceutical formulation of claim 5, wherein (c) is arginine/arginine-HCl.

7. The pharmaceutical formulation of claim 5 or 6, wherein the formulation comprises about 220 mM of (c).

8. The pharmaceutical formulation of any one of claims 1-4, wherein (c) is sucrose.

9. The pharmaceutical formulation of claim 8, wherein the formulation comprises about 240 mM of (c).

10. The pharmaceutical formulation of any one of claims 1-9, wherein the formulation comprises about 0.03% to about 0.05% (w/v) of (d).

11. The pharmaceutical formulation of any one of claims 1-10, wherein (d) is polysorbate 80.

12. The pharmaceutical formulation of any one of claims 1-11, wherein the formulation has a pH of about 6.0.

13. A pharmaceutical formulation comprising:

(a) a first antibody or antigen-binding fragment thereof that binds to a spike protein of SARS-CoV-2 and a second antibody or antigen-binding fragment thereof that binds to a spike protein of SARS-CoV-2,

(b) about 20 mM histidine and/or a pharmaceutically acceptable salt thereof,

(c) about 220 mM arginine and/or a pharmaceutically acceptable salt thereof, and

(d) about 0.04% (w/v) polysorbate80,

wherein the formulation has a pH of about 6.0.

14. The pharmaceutical formulation of any one of claims 1-13, wherein the formulation comprises about 135 mg/mL to about 165 mg/mL of (a).

15. The pharmaceutical formulation of any one of claims 1-14 wherein the formulation comprises about 150 mg/mL of (a).

16. The pharmaceutical formulation of any one of claims 1-15, wherein the formulation comprises about a 1:1 ratio of the first antibody or antigen-binding fragment thereof and the second antibody or antigen-binding fragment thereof.

17. The pharmaceutical formulation of any one of claims 1-16, wherein the formulation is about 2 mL.

18. The pharmaceutical formulation of any one of claims 1-17, wherein the formulation comprises about 300 mg of (a).

19. The pharmaceutical formulation of any one of claims 1-18, wherein

the first antibody or antigen-binding fragment thereof comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:1, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:2, a VH CDR3 comprising the amino acid sequence of SEQ ID NO:3, a VL CDR1 comprising the amino acid sequence of SEQ ID NO:4, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:5, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:6; and/or

the second antibody or antigen-binding fragment thereof comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:9, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:10, a VH CDR3 comprising the amino acid sequence of SEQ ID NO:11, a VL CDR1 comprising the amino acid sequence of SEQ ID NO:12, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:13, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:14.

20. The pharmaceutical formulation of any one of claims 1-19, wherein the first antibody or antigen-binding fragment thereof comprises a variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO:7 and a variable light chain (VL) comprising the amino acid sequence of SEQ ID NO:8; and/or the second antibody or antigen-binding fragment thereof comprises a variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO:15 and a variable light chain (VL) comprising the amino acid sequence of SEQ ID NO:16.

21. The pharmaceutical formulation of any one of claims 1-20, wherein the first antibody or antigen-binding fragment thereof is an IgG and/or the second antibody or antigen-binding fragment thereof is an IgG.

22. The pharmaceutical formulation of any one of claims 1-21, wherein the first antibody or antigen-binding fragment thereof is an IgG1 and/or the second antibody or antigen-binding fragment thereof is an IgG1.

23. The pharmaceutical formulation of any one of claims 1-22, wherein the first antibody or antigen-binding fragment thereof comprises a YTE mutation and/or the second antibody or antigen-binding fragment thereof comprises a YTE mutation.

24. The pharmaceutical formulation of any one of claims 1-23, wherein the first antibody or antigen-binding fragment thereof comprises a TM mutation and/or the second antibody or antigen-binding fragment thereof comprises a TM mutation.

25. The pharmaceutical formulation of any one of claims 1-24, wherein the first antibody or antigen-binding fragment thereof comprises a heavy chain comprising amino acids 1-460 of SEQ ID NO:17 and a light chain comprising the amino acid sequence of SEQ ID NO:18 and/or wherein the second antibody or antigen-binding fragment thereof comprises a heavy chain comprising amino acids 1-460 of SEQ ID NO:19 and a light chain comprising the amino acid sequence of SEQ ID NO:20.

26. A pharmaceutical formulation comprising:

(a) an antibody or antigen-binding fragment thereof that binds to a spike protein of SARS-CoV-2,

(b) about 20 mM histidine/histidine-HCl,

(c) about 240 mM sucrose, and

(d) about 0.04% (w/v) polysorbate 80,

wherein the formulation has a pH of 6.0.

27. The pharmaceutical formulation of any one of claims 1-12 and 26, wherein the formulation comprises about 100 mg/mL of (a).

28. The pharmaceutical formulation of any one of claims 1-12, 26, and 27, wherein the formulation is about 1.5 mL.

29. The pharmaceutical formulation of any one of claims 1-12 and 26-28, wherein the formulation comprises about 150 mg of (a).

30. The pharmaceutical formulation of any one of claims 1-12 and 26-29, wherein

the antibody or antigen-binding fragment thereof comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:1, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:2, a VH CDR3 comprising the amino acid sequence of SEQ ID NO:3, a VL CDR1 comprising the amino acid sequence of SEQ ID NO:4, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:5, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:6; or

the antibody or antigen-binding fragment thereof comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:9, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:10, a VH CDR3 comprising the amino acid sequence of SEQ ID NO:11, a VL CDR1 comprising the amino acid sequence of SEQ ID NO:12, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:13, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:14.

31. The pharmaceutical formulation of any one of claims 1-12 and 26-30 wherein

the antibody or antigen-binding fragment thereof comprises a variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO:7 and a variable light chain (VL) comprising the amino acid sequence of SEQ ID NO:8; or

the antibody or antigen-binding fragment thereof comprises a variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO:15 and a variable light chain (VL) comprising the amino acid sequence of SEQ ID NO:16.

32. The pharmaceutical formulation of any one of claims 1-12 and 26-31, wherein the antibody or antigen-binding fragment thereof is an IgG.

33. The pharmaceutical formulation of any one of claims 1-12 and 26-32, wherein the antibody or antigen-binding fragment thereof is an IgG1.

34. The pharmaceutical formulation of any one of claims 1-12 and 26-33, wherein the antibody or antigen-binding fragment thereof comprises a YTE mutation.

35. The pharmaceutical formulation of any one of claims 1-12 and 26-34, wherein the antibody or antigen-binding fragment thereof comprises a TM mutation.

36. The pharmaceutical formulation of any one of claims 1-12 and 26-35, wherein

the antibody or antigen-binding fragment thereof comprises a heavy chain comprising amino acids 1-460 of SEQ ID NO:17 and a light chain comprising the amino acid sequence of SEQ ID NO:18; or

the antibody or antigen-binding fragment thereof comprises a heavy chain comprising amino acids 1-460 of SEQ ID NO:19 and a light chain comprising the amino acid sequence of SEQ ID NO:20.

37. The pharmaceutical formulation of any one of claims 1-36, formulated for intramuscular injection.

38. The pharmaceutical formulation of any one of claims 1-37, formulated for direct injection into the lateral thigh, gluteal dorsal, or gluteal ventral.

39. The pharmaceutical formulation of any one of claims 1-38, wherein the formulation is stable at 2-8°C for at least 12 months.

40. The pharmaceutical formulation of any one of claims 1-39, wherein the formulation is stable at room temperature for at least 1 week or for at least 2 weeks.

41. A vial comprising the pharmaceutical formulation of any one of claims 1-40.

42. A syringe comprising the pharmaceutical formulation of any one of claims 1-40.

43. A kit comprising a first pharmaceutical formulation of any one of claims 1-12 and 26-40 and a second pharmaceutical formulation of any one of claims 1-12 and 26-40, wherein

the first formulation comprises an antibody or antigen-binding fragment thereof comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:1, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:2, a VH CDR3 comprising the amino acid sequence of SEQ ID NO:3, a VL CDR1 comprising the amino acid sequence of SEQ ID NO:4, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:5, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:6; and

the second formulation comprises an antibody or antigen-binding fragment thereof comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:9, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:10, a VH CDR3 comprising the amino acid sequence of SEQ ID NO:11, a VL CDR1 comprising the amino acid sequence of SEQ ID NO:12, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:13, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:14.

44. The kit of claim 43 wherein

the first formulation comprises an antibody or antigen-binding fragment thereof comprising a variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO:7 and a variable light chain (VL) comprising the amino acid sequence of SEQ ID NO:8; or

the second formulation comprises an antibody or antigen-binding fragment thereof comprising a variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO:15 and a variable light chain (VL) comprising the amino acid sequence of SEQ ID NO:16.

45. The kit of claim 43 or 44, wherein

the first formulation comprises an antibody or antigen-binding fragment thereof comprising a heavy chain comprising amino acids 1-460 of SEQ ID NO:17 and a light chain comprising the amino acid sequence of SEQ ID NO:18; or

the second formulation comprises an antibody or antigen-binding fragment thereof comprising a heavy chain comprising amino acids 1-460 of SEQ ID NO:19 and a light chain comprising the amino acid sequence of SEQ ID NO:20.

46. The pharmaceutical formulation, vial, syringe, or kit of any one of claims 1-45 for use in a method of treating or preventing Coronavirus Disease 2019 (COVID-19) in a subject.

47. Use of the pharmaceutical formulation, vial, syringe, or kit of any one of claims 1-45 in the manufacture of a medicament for treating or preventing Coronavirus Disease 2019 (COVID-19) in a subject.

48. The pharmaceutical formulation, vial, syringe, kit, or method of claim 46 or 47, wherein the method prevents or decreases the severity of one or more symptoms of COVID-19.

49. The pharmaceutical formulation, vial, syringe, kit, or method of any one of claims 45-48, wherein the subject has been exposed to SARS-CoV-2.

50. The pharmaceutical formulation vial, syringe, kit, or method of any one of claims 45-48, wherein the subject does not have a known exposure to SARS-CoV-2.

51. The pharmaceutical formulation vial, syringe, kit, or method of any one of claims 45-50, wherein the subject is less than 70 kg.

52. The pharmaceutical formulation vial, syringe, kit, or method of any one of claims 45-50, wherein the subject is at least 70 kg and less than 80 kg.

53. The pharmaceutical formulation vial, syringe, kit, or method of any one of claims 45-50, wherein the subject is at least 80 kg.

54. The pharmaceutical formulation vial, syringe, kit, or method of any one of claims 45-53, wherein the subject has received an anti-SARS-CoV-2 vaccination.

55. The pharmaceutical formulation vial, syringe, kit, or method of any one of claims 45-54, wherein the subject has received at least two anti-SARS-CoV-2 vaccinations.

56. The pharmaceutical formulation vial, syringe, kit, or method of any one of claims 45-53, wherein the subject has not received an anti-SARS-CoV-2 vaccination.

57. The pharmaceutical formulation vial, syringe, kit, or method of any one of claims 45-56, wherein the subject has a BMI of 18 to 30 kg/m2.